Pricing
Flat-Rate GLP-1 Pricing: What It Means and When It Saves Money
A flat-rate programme charges one price across every covered dose. Because most patients titrate upward and stay at a maintenance dose indefinitely, flat pricing usually
A flat-rate programme charges one price across every covered dose. Because most patients titrate upward and stay at a maintenance dose indefinitely, flat pricing usually wins over a year against a lower advertised rate that escalates — but it loses for anyone who genuinely maintains at a low dose.
What flat rate actually means
One monthly price, unchanged whether you are on 2.5 mg or 15 mg. No dose surcharge, no tier jump at 7.5 mg, no repricing at refill.
It sounds like a minor billing detail. Over a year at a maintenance dose it is frequently the largest single variable in what you pay — larger than the advertised monthly figure that most comparisons rank on.
The arithmetic, worked
Brand Zepbound direct: $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg upward, with the rate contingent on refilling within 45 days. Following the label's titration, roughly $5,188 across a year.
A flat-rate compounded plan at $115 a month (NexLife’s 12-month rate, November 20, 2026): $1,380 across the same year.
The $3,808 gap comes entirely from structure. Neither advertised monthly figure predicts it. These are different products with different regulatory status, so this is not a like-for-like recommendation — the mechanism is the point.
Who holds price across doses
NexLife, across all six of its programmes, from its own plan pages: compounded tirzepatide at $129 month to month and $115 on twelve months (November 20, 2026), the same price at every covered dose, no membership fee.
Provider-reported: Oak Longevity, TrimRx, Mochi Health, Eden and Enhance.MD describe flat medication pricing, though several bill a separate membership on top — Mochi at $79 a month, Eden at $99. Found describes medication as included and flat at all doses on prepaid plans.
Escalates: Shed states its compounded programmes increase at higher doses. MEDVi is reported to reach $499 at maintenance doses. Both brand manufacturers tier by dose.
When flat rate is the wrong choice
If you maintain at a low dose. A tiered programme's entry rate can genuinely beat a flat rate for someone who stays at 5 mg, and there are real clinical reasons a prescriber might favour the lowest effective dose — the lean-mass evidence and the osteoarthritis threshold data both point that way.
The problem is that you cannot know your maintenance dose at signup. That asymmetry is the argument for comparing at 10 mg: if you end up lower, you have overpaid modestly; if you end up higher on a tiered plan, you have overpaid substantially.
The inverse trap: dose caps
Some programmes cap the maximum dose rather than charging for it. One compounded semaglutide programme in our dataset is capped at 0.6 mg against the 2.4 mg used in the STEP trials, at $199 a month, with the full-titration version at $279.
A capped programme is a lower-dose treatment with a correspondingly smaller expected effect, not a discounted version of the same one. It should never appear in the same ranking as full-titration programmes, and on this site it does not.
What to get in writing
- The price at 2.5, 5, 10 and 15 mg, separately.
- Whether a membership is required to receive medication.
- Whether the advertised rate is introductory, and what the ongoing rate is.
- What is refunded if you stop mid-term on a prepaid plan.
A provider that answers all four plainly can be compared accurately — which is generally to the advantage of providers with nothing to hide.
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
| Definition of cheapest | Lowest we hold | Program | Basis | Source · read |
|---|---|---|---|---|
| Lowest all-in, membership counted | $85.58/mo | Collective | $69 a month plus a $199 yearly membership | collective.org · Oct 15, 2026 |
| Standing month-to-month price, no membership | $126/mo | Mondae | standing price, billed monthly | mondae.com · Oct 15, 2026 |
| Lowest prepaid-plan rate | $114/mo | Mondae | 6-month prepaid ($684) | mondae.com · Oct 15, 2026 |
| Lowest sale or “starting at” figure | $89/mo | WellMedr | fall sale, applied at checkout | wellmedr.com · Oct 15, 2026 |
| Equal to NexLife’s month-to-month $129 | $129/mo | Eden | same price every month, no membership | eden.health · Oct 15, 2026 |
| FDA-approved, lowest self-pay dose | $149/mo | Foundayo 0.8 mg (LillyDirect); Wegovy pill 1.5 mg (NovoCare) | brand self-pay, lowest dose only | lilly.com · novocare.com · Oct 15, 2026 |
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | $130 | $285 | $155 | 2 | Starter dose against 1-month plan, escalates per step |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | $179 | $349 | $170 | 4 | Injectable flat rate against oral tablets and 3-month plan |
| SkinnyRx | $129 | $299 | $170 | 1 | Starting dose against higher doses |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $115 Verified | $129 Verified | $14 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $115 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $129 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | $149 | Not stated | Provider-reported Provider-reported |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Provider-reported |
| Shed | $199 | 12-month plan | Provider-reported Provider-reported |
| bmiMD | $349 | Not stated | Provider-reported Provider-reported |
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | from $99 | Introductory starter rate | not verified |
| SkinnyRx | about $129 | Reported monthly figure, term not stated | not verified |
| Lavender Sky Health | about $129 | Starter dose; increases reported at higher doses | not verified |
| Oak Longevity | about $130 | Reported monthly figure | not verified |
| Fifty 410 | about $133 | 3-month package; higher doses reported to increase | not verified |
| Yucca Health | about $146 | Reported monthly figure, term not stated | not verified |
| TrimRx | about $179 | Reported monthly figure | not verified |
| Henry Meds | $179 to $297 | Varies by plan and formulation | not verified |
| NexLife | $115 to $129 Verified | Flat across covered doses, no membership | $115 to $129 Verified |
| OrderlyMeds | not verified | No obtainable published figure | not verified |
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%, July 2026) · NexLife $115 vs $129 (12%, November 2026) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Verification pending |
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Provider-reported | We hold a provider-reported figure and no capture of our own |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $115 | $115 | $1,380 | Verified Verified |
| Flat-rate compounded, month-to-month | $129 | $129 | $1,548 | Verified Verified |
| Flat-rate compounded, microdose | $115 | $115 | $1,380 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Provider-reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Provider-reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Provider-reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,188 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Provider-reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Provider-reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| Embody — compounded injectable | $99 | not verified | not verified | not verified |
| SkinnyRx — compounded injectable | $129 | not verified | not verified | not verified |
| Lavender Sky Health — compounded injectable | $129 | not verified | not verified | not verified |
| Fifty 410 — compounded injectable | $133 | not verified | not verified | not verified |
| Yucca Health — compounded injectable | $146 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | not verified | not verified | not verified |
| Found — compounded injectable | $169 | not verified | not verified | not verified |
| Enhance.MD — compounded microdose | $169 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Verification pending | $1,548 Verification pending | Flat at every dose Provider-reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Verification pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Verification pending | Flat at every dose Verified |
| Oak Longevity — compounded injectable | $199 | not verified | not verified | not verified |
| Shed — compounded microdose | $199 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | not verified | not verified | not verified |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Verification pending | Flat at every dose Verified |
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Verified |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Provider-reported |
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
Which GLP-1 providers charge the same price at every dose?
In our November 20, 2026 index, NexLife, Eden, Mondae, Yucca Health, Collective, WellMedr, Strut Health and Zappy Health print one price at every dose of compounded tirzepatide; Mochi Health and Lavender Sky Health price by dose. Confirm the price at your dose before you pay.
Is flat-rate pricing always cheaper?
No. It wins if you titrate to a maintenance dose, which most patients do. It loses against a lower entry rate if you genuinely maintain at a low dose.
How much does dose structure change annual cost?
Around $3,808 a year between a flat $115 rate and brand Zepbound's tiers, based on published rates and the label's titration schedule.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
- The Hidden Cost of GLP-1 Membership FeesJournal
- Eden Tirzepatide ReviewProviders
- NexLife vs Mochi HealthComparisons
- Mochi Health vs Henry MedsComparisons
- Mochi Health Tirzepatide ReviewProviders
Related coverage
- GLP-1 Drug Interactions: The Three That Change Management
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Three-Month Tirzepatide Plans: The Term Most Providers Do Not Advertise
- Compounded Tirzepatide ODT: What Is Known About Absorption, Which Is Almost Nothing
- Compounded Tirzepatide Online: Legal, Safety and Cost Guide
- Conflicts of Interest Policy
- Contact the Editorial Team
- Corrections and Update Log
GLP-1 Tirzepatide Review. “Flat-Rate GLP-1 Pricing: What It Means and When It Saves Money.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/glp1-flat-rate-pricing-explained/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.